Choosing the right dividend stock isn't just about chasing the highest yields. The best dividend stocks are often the ones that quietly raise their payouts year after year while continuing to grow the underlying business. This is precisely why Abbott Laboratories (ABT) has been a favorite among income-seeking investors. The healthcare giant has a five-decade track record of dividend increases, earning a spot among the market's prestigious Dividend Kings.
Despite another strong quarter where it beats consensus forecasts, ABT stock is down 19% year-to-date (YTD), trailing the S&P 500 Index ($SPX). But this dip could be a great opportunity for long-term dividend investors to grab one of the safest income stocks.
AI Startup Moonshot Just Launched Its Record-Setting Kimi K3 Model. Buy Alibaba Stock to Benefit.
As the AI Selloff Worsens, Time-Tested Procter & Gamble Stock Could Be the Biggest Winner
TSMC's AI Boom Is Just Getting Started: Why Investors Should Buy the Pullback in TSM Stock Now
Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment – delivered right when you need the info most. Subscribe today!
Abbott is not only a Dividend King with a 55-year track record of dividend hikes, but it also offers a forward dividend yield of 2.5%, higher than the healthcare sector average. The sole reason Abbott has been able to consistently pay and increase dividends is its diversified healthcare business. Many healthcare companies rely on the success of one blockbuster drug or a single product category. But Abbott Labs operates through four key segments—medical devices, diagnostics, nutrition, and established pharmaceuticals.
These multiple revenue streams led to another strong quarter where it beat Wall Street's estimates for both the top line and the bottom line. In the second quarter, total sales increased 13% year-over-year (YoY) to $12.6 billion, higher than the forecasted revenue of $12.52 billion. Similarly, adjusted EPS of $1.31 came in higher than the forecast of $1.28. Despite a challenging macroeconomic environment, diagnostic testing volumes remain strong across both the U.S. and international markets. Notably, its U.S. core laboratory business grew 7.5%. As diagnostic tests influence around 70% of healthcare decisions, this testing volume growth reflects the strength of underlying healthcare demand.
Source: Yahoo Finance Top News — This article was automatically imported from the source. Read full article at original source →
